Abstract / Summary
To quantify how specific sleep-disorder phenotypes are related to incident heart failure (HF) using a meta-analysis of cohort data and to probe causal relevance via 2-sample Mendelian randomization (MR). Fourteen cohorts comprised of participants without HF at baseline were pooled (49,501 exposed; 337,317 controls). A random effects meta-analysis produced pooled hazard ratios (HRs) with 95% confidence intervals (CIs). A bidirectional two-sample MR was used to evaluate the causal effects of sleep phenotypes on HF. Overall, sleep disorders were linked to a higher incidence of HF (pooled HR 1.46; 95% CI 1.30-1.63; p<0.001). In terms of phenotype, obstructive sleep apnea (OSA) was significantly associated (pooled HR 1.39; 95% CI 1.18-1.64; p < 0.001), whereas insomnia was not independently associated with HF (pooled HR 1.11; 95% CI 0.75-1.62; p = 0.609). The MR analyses supported a causal effect of OSA on HF (inverse-variance weighted odds ratio 1.12; 95% CI 1.03-1.23; p = 0.007) and revealed no causal evidence for insomnia. Sleep disorders are associated with increased HF risk, which varies by phenotype. Convergent observational and genetic evidence implicates OSA in increased HF risk, whereas insomnia shows no independent or causal association. These findings prioritize OSA screening and targeted prevention in HF risk mitigation.
Primary Source
Saudi medical journal
Ask Prognia AI
Have questions about this meta-analysis?
Prognia AI can search this source alongside 35M+ PubMed papers and current ESC, AHA, NICE, and ADA guidelines to give you a fully cited clinical answer.
Related Clinical Guidelines
Related Blog Posts
ESC 2023 Heart Failure Guidelines: What Every Cardiologist Needs to Know
The 2023 focused update to the ESC Heart Failure Guidelines introduced key changes to SGLT2 inhibitor recommendations, HFmrEF management, and device therapy thresholds. Here is a practical summary.
CHADS₂-VASc in Practice: When to Start Anticoagulation in AF
A practical walkthrough of the CHADS₂-VASc scoring system, its ESC guideline thresholds, and how to use it alongside HAS-BLED to counsel patients with atrial fibrillation.